(Q38856722)

7 September 2017

Targeted agents and immunotherapies: optimizing outcomes in melanoma (English)

1 reference

7 September 2017

1 reference

2

Keith T Flaherty

1 reference

7 September 2017

4

Georgina V Long

1 reference

7 September 2017

3

Antoni Ribas

1 reference

7 September 2017

Jason J Luke

1

1 reference

PubMed ID

28374786

7 September 2017

language of work or name

English

0 references

publication date

4 April 2017

1 reference

Nature Reviews Clinical Oncology

7 September 2017

1 reference

7 September 2017

14

1 reference

7 September 2017

463-482

1 reference

7 September 2017

8

1 reference

Chemotherapy in the management of advanced cutaneous malignant melanoma

7 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Genomic Classification of Cutaneous Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

A cell cycle regulator potentially involved in genesis of many tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

The Genetic Evolution of Melanoma from Precursor Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Large-scale analysis of KIT aberrations in Chinese patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF inhibitor activity in V600R metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Regulatory circuits of T cell function in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Resistance to BRAF inhibition in melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF and MEK inhibition in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Talimogene Laherparepvec for the Treatment of Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Gauging the Long-Term Benefits of Ipilimumab in Melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Isolation and molecular characterization of circulating melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Brn-2 Represses Microphthalmia-Associated Transcription Factor Expression and Marks a Distinct Subpopulation of Microphthalmia-Associated Transcription Factor-Negative Melanoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.43

7 January 2021

inferred from DOI database lookup

Missense mutations of the BRAF gene in human lung adenocarcinoma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28374786

12 December 2020

inferred from PubMed ID database lookup

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28374786

12 December 2020

inferred from PubMed ID database lookup

Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28374786

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NRCLINONC.2017.43

1 reference

7 September 2017

1 reference

PubMed ID

28374786